BACKGROUND COVID-19 convalescent plasma (CCP) has been considered a treatment
option for COVID-19. This trial assessed the efficacy of a neutralizing antibody containing …

BACKGROUND Results of many randomized trials on COVID-19 convalescent plasma
(CCP) have been reported, but information on long-term outcome after CCP treatment is …

Background The effects of convalescent plasma (CP) therapy in hospitalised patients with
coronavirus disease 2019 (COVID-19) remain uncertain. This study investigates the effect of …

Objective To study the effectiveness of COVID-19 convalescent plasma (CCP) therapy for
patients with moderate and severe COVID-19 disease. Methods This non-randomized …

Introduction When the COVID-19 pandemic struck no specific therapies were available and
many turned to COVID-19 convalescent plasma (CCP), a form of antibody therapy. The …

Data on convalescent plasma (CP) treatment in COVID-19 outpatients are scarce. We aimed
to assess whether CP administered during the first week of symptoms reduced the disease …

Objectives The potential benefit of convalescent plasma (CP) therapy for coronavirus
disease 2019 (COVID-19) is highest when administered early after symptom onset. Our …

Background Antibody-based strategies for COVID-19 have shown promise in prevention
and treatment of early disease. COVID-19 convalescent plasma (CCP) has been widely …

Background We assessed outcome of patients with moderate and severe COVID-19
following treatment with convalescent plasma (CP) and the association with IgG levels in …

Convalescent plasma can provide passive immunity during viral outbreaks, but the benefit is
uncertain for the treatment of novel coronavirus disease 2019 (COVID‐19). Our goal is to …